Power Law company profile

Arcus Biosciences

Biotech & Life Sciences · Hayward, United States · Founded 2015 · IPO 2018 Unicorn

Exciting young company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology

Valuation

$2.33B

Market cap · May/2026

Revenue

$247M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Investors

12 investors on Arcus Biosciences's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 2 investors entered at this stage

Celgene

The Column Group

Series B+ 10 investors entered at this stage

Wellington Management

EcoR1 Capital

Foresite Capital

Decheng Capital

Novartis

Aisling Capital

Taiho Pharma

Invus

RTA Capital

Global footprint

Where Arcus Biosciences has talent and traffic

AI talent share

0.3% of workforce is AI talent
(2 of 655 staff)

Core AI00%

Other AI20.31%

Non-AI workforce65399.69%

Workforce by country

15 countries with
team presence

🇺🇸 United States97.3%

🇰🇷 South Korea0.4%

🇻🇪 Venezuela0.2%

🏳️ Sudan0.2%

🇮🇳 India0.2%

Top 5 of 15 shown

Web traffic by country

14K monthly visits
across markets

🇺🇸 United States65%

🇮🇳 India13.6%

🇬🇧 United Kingdom10.7%

🇨🇦 Canada4.3%

🇯🇵 Japan2.9%

Top 5 markets shown

Patent intelligence

$74M patent portfolio · 68 active families

Estimated portfolio value

$74M

3.2% of market cap · 7.1× smaller than top peer ChemoCentryx ($524M)

68 active patent families

Where Arcus Biosciences innovates DiseaseCarcinosisMolecular biologyPharmacologyCancer research

Where Arcus Biosciences concentrates vs peers

Each axis is a top-10 topic across Arcus Biosciences and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Arcus Biosciences

An AI-synthesized read of the highest-engagement posts about Arcus Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Arcus Biosciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles